Stable Isotope SCFA Tracing for Accurate Metabolic Rate Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring short-chain fatty acid production in the colon are inaccurate due to high absorption by colonocytes and metabolism by the liver, making it difficult to estimate production levels in humans, which is crucial for understanding their impact on health and diagnosing related diseases.
Innovation Solution
A method involving the administration of stable isotope labeled short-chain fatty acids intravenously, followed by blood sample analysis to calculate metabolic rates, with additional administration of soluble fiber to assess production deficiencies, and comparison with healthy controls for disease diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods measure short-chain fatty acid content in feces or plasma, then measurement can be performed, but the measurement precision is poor due to high absorption by colonocytes and metabolism by the liver
Solution Approach 1:
The patent uses stable isotope-labeled short-chain fatty acids as an intermediary tracer substance. This labeled tracer allows indirect measurement of endogenous short-chain fatty acid production by comparing the isotopic enrichment in plasma against a known administered dose, bypassing the problem of direct measurement interference from colonocyte absorption and hepatic metabolism.
Solution Approach 2:
The patent creates a copy of the endogenous short-chain fatty acid system using stable isotope-labeled analogs. These labeled copies behave identically to natural short-chain fatty acids in terms of absorption and metabolism, allowing accurate tracking and quantification of production rates without interfering with normal physiological processes.
2Measurement precision
If stable isotope labeled short-chain fatty acid is administered intravenously, then accurate metabolic rate calculation is enabled, but the device complexity and procedural complexity increase
Solution Approach 1:
The patent changes the chemical parameter of the short-chain fatty acid by introducing stable isotope labels (e.g., 13C, 15N). This parameter change allows the substance to be tracked through metabolic processes using mass spectrometry or NMR, enabling precise metabolic rate calculations while maintaining the natural biochemical behavior of the original molecule.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Accurately determines short-chain fatty acid production and deficiency, enabling effective diagnosis of pulmonary and neurological disorders by measuring metabolic rates and comparing them to healthy controls.
Implementation Method 1
administration of stable isotope labeled short-chain fatty acids intravenously, followed by blood sample analysis to calculate metabolic rates
Data Source
AI summary
Provided herein are methods for determining a metabolic rate for at least one endogenous short-chain fatty acid in a subject, for diagnosing a pulmonary disease in a subject and for diagnosing a neurological disorder in a subject. Generally in the methods stable isotope labeled short-chain fatty acid are pulsed and metabolic rates are calculated in a first baseline blood sample and in a series of second blood samples obtained at intervals. The metabolic rates provide information about fatty acid metabolism and production.